Keyphrases
Phase II Study
100%
Allogeneic
100%
Cryopreserved
100%
Dendritic Cell-based Immunotherapy
100%
Tumor Lysate
100%
Urological Cancer
100%
Vaccination
66%
Aliquot
66%
Dendritic Cell Vaccine
66%
T Cells
33%
Disease Progression
33%
Tumor
33%
Cell-based
33%
Clinical Application
33%
Interferon-γ
33%
IL-1 Family Cytokines
33%
Interleukin-10
33%
Lysate
33%
Hormone-sensitive Prostate Cancer
33%
T Helper 1
33%
Immunogenicity
33%
Renal Cell Carcinoma
33%
Quality Control
33%
Cellular Immunity
33%
Humoral Immunity
33%
ELISPOT
33%
Cell Infiltration
33%
Phenotypic Expression
33%
Metastatic Renal Cell Carcinoma (mRCC)
33%
Repeated Administration
33%
Cryopreservation
33%
Delayed Hypersensitivity
33%
Prostate-specific Antigen Density
33%
Prostate-specific Antigen Doubling Time
33%
Rechallenge
33%
Allogeneic Mixed Lymphocyte Reaction
33%
Pulsed DC
33%
In Vitro Assessment
33%
Prostate-specific Antigen
33%
Skin Test
33%
Skin Biopsy
33%
Buffy Coat
33%
Keyhole Limpet Hemocyanin
33%
Response Assessment
33%
Medicine and Dentistry
Neoplasm
100%
Urinary Tract Cancer
100%
Prostate Specific Antigen
100%
Dendritic Cell Immunotherapy
100%
Adjuvant
100%
Dendritic Cell Vaccine
66%
Clinical Study
33%
In Vitro
33%
T Cell
33%
Enzyme Linked Immunospot Assay
33%
Immunotherapy
33%
Cytokine
33%
Gamma Interferon
33%
Disease Exacerbation
33%
Interleukin 10
33%
Clear Cell Renal Cell Carcinoma
33%
Cellular Immunity
33%
Humoral Immunity
33%
Dendritic Cell
33%
Cellular Infiltration
33%
Kidney Metastasis
33%
Cryopreservation
33%
Immunogenicity
33%
Skin Test
33%
Castration Resistant Prostate Cancer
33%
Keyhole Limpet Hemocyanin
33%
Delayed Hypersensitivity
33%
Repeated Drug Dose
33%
Skin Biopsy
33%
Mixed Lymphocyte Reaction
33%
Diseases
33%
Immunology and Microbiology
Cell Lysate
100%
Adjuvant
100%
Prostate Specific Antigen
100%
Dendritic Cell Immunotherapy
100%
Carcinoma Cell
66%
Dendritic Cell Vaccine
66%
T Cell
33%
Immunotherapy
33%
Cytokine
33%
Dendritic Cell
33%
Interleukin 10
33%
Interferon Gamma
33%
Immunogenicity
33%
Adoptive Immunity
33%
Humoral Immunity
33%
ELISPOT
33%
Prostate
33%
Keyhole Limpet Hemocyanin
33%
Mixed Lymphocyte Reaction
33%
Cryopreservation
33%
Repeated Drug Dose
33%
Buffy Coat
33%
Delayed Hypersensitivity
33%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Immunotherapy
100%
Adjuvant
100%
Prostate Specific Antigen
100%
Urinary Tract Cancer
100%
Dendritic Cell Vaccine
66%
Clinical Study
33%
Cytokine
33%
Gamma Interferon
33%
Disease Exacerbation
33%
Interleukin 10
33%
Renal Cell Carcinoma
33%
Immunogenicity
33%
Kidney Metastasis
33%
Castration Resistant Prostate Cancer
33%
Keyhole Limpet Hemocyanin
33%
Delayed Hypersensitivity
33%
Diseases
33%